T-1105

T-1105, a structural analogue of T-705, is a novel broad-spectrum viral polymerase inhibitor. T-1105 inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite. T-1105 has antiviral activity against various RNA viruses. T-1105 can be formed by nicotinamide mononucleotide adenylyltransferase^[1][2]. IC50 & Target: EC50: 17 μM (parainfluenza-3 virus); EC50: 24 μM (Punta Toro virus) ^[3].
EC50: 97.5 μM (ZIKV strain SZ01) ^[4] In Vitro: T-1105 has antiviral activity against various RNA viruses, including Zika virus (ZIKV), influenza virus, arenaviruses, bunyaviruses, West Nile virus (WNV), yellow fever virus (YFV), and foot-and-mouth disease virus (FMDV)^[1][2].
T-1105 has good anti-RNA virus activity with values EC₅₀ of 17 μM and 24 μM for parainfluenza-3 virus and Punta Toro virus in MDCK cells^[3].
T-1105 is a potential inhibitor of Zika virus replication^[4].
T-1105 can inhibit the SFTSV replication with an value IC₅₀ of 49 μM in Vero cells and is not affect cell viability in 0-3 μM^[5]. In Vivo: T-1105 (Oral, 200 mg/kg, twice daily for 6 days) effectively inhibits the virus replication in the infected pigs^[6].